Table 1 Patient and tumor characteristics
Characteristic | UAB discovery dataset | Fox chase validation dataset | ||
|---|---|---|---|---|
Number (N = 159), % | Recurrers (N = 33), % | Number (N = 198), % | Recurrers (N = 53), % | |
Median Age | 58 | 59 | 61 | 59 |
Gender | ||||
Female | 60 (37.8) | 11 (33.3) | 55 (27.7) | 13 (24.5) |
Male | 99 (62.2) | 22 (66.7) | 143 (72.2) | 40 (75.4) |
Race | ||||
Caucasian | 124 (77.9) | 30 (90.9) | 190 (96) | 51 (96.2) |
AA | 19 (12.0) | 2 (6) | 6 (3.0) | 2 (3.7) |
Other | 16 (10.1) | 1 (3) | 2 (1) | 0 (0) |
Median Follow-up | 48.3 mo (24.5–120.5) | 56 mo (25.5–119.7) | 70.92 (15.4–126.9) | 61.9 mo (16.2–126.9) |
Median time to recurrence | 25.8 mo (4.2–114.7) | 18.4 mo (2.3–85.3) | ||
Pathologic T stage | ||||
T1 / T2 / T3/ T4 | 62 / 20 / 77 / 0(38.9 / 12.6 / 48.5) | 4 / 6 / 23 / 0 (12.1 / 18.1 / 69.7) | 89 / 31 / 76 / 2 (45 / 15.6 / 38.3 / 1) | 17 / 6 / 28 / 2 (32 / 11.3 / 52.8 / 3.7) |
Grade | ||||
1–2 | 43 (27) | 6 (18.1) | 58 (29.2) | 9 (16.9) |
3–4 | 116 (73) | 27 (81.8) | 140 (70.7) | 44 (83) |
Necrosis | ||||
Yes | 48 (30.2) | 18 (54.5) | 61 (30.8) | 28 (52.8) |
No | 111 (69.8) | 15 (45.4) | 137 (69.1) | 25 (47.1) |
Lymphocyte infiltration scoring | ||||
0 | 10 (6.2) | 0 (0) | 27 (13.6) | 5 (9.4) |
1 | 56 (35.2) | 7 (21.2) | 44 (22.2) | 10 (18.9) |
2 | 30 (18.8) | 9 (27.2) | 48 (24.2) | 9 (17) |
3 | 33 (20.7) | 7 (21.2) | 31 (15.6) | 10 (18.9) |
4 | 30 (18.8) | 10 (30.3) | 48 (24.2) | 19 (35.8) |